@article {Philip:May-June 2007:1088-5412:296,
	author = "Philip, George",
	author = "Williams-Herman, Debora",
	author = "Patel, Piyush",
	author = "Weinstein, Steven F.",
	author = "Alon, Achilles",
	author = "Gilles, Leen",
	author = "Tozzi, Carol A.",
	author = "Dass, S. Balachandra",
	author = "Reiss, Theodore F.",
	title = "Efficacy of montelukast for treating perennial allergic rhinitis",
	journal = "Allergy and Asthma Proceedings",
	volume = "28",
	year = "May-June 2007",
	abstract = "Perennial allergic rhinitis (PAR) is a chronic inflammatory nasal condition in individuals exposed year-round to allergens. This was a double-blind study of 15- to 85-year-old patients randomly allocated to montelukast, 10 mg (n &#61; 630), placebo (n &#61; 613), or the positive control cetirizine, 10 mg (n &#61; 122) for 6 weeks. The primary efficacy end point was change from baseline in Daytime Nasal Symptoms Score (DNSS; mean of congestion, rhinorrhea, sneezing, and itching scores, rated daily by patients &#91;scale: 0 &#61; none to 3 &#61; severe&#93;) averaged during the initial 4 weeks (primary analysis) or entire 6 weeks of treatment. Also assessed were combined <I>post hoc</I> results of primary end point data from this study and another similarly designed study (Patel P, <I>et al.</I> Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis, Ann Allergy Asthma Immunol 95:551, 2005). Over 4 weeks, montelukast showed numerical improvement over placebo in DNSS (least-squares mean difference of &#8722;0.04 &#91;95&#37; confidence interval &#123;CI&#125;, &#8722;0.09, 0.01&#93;); the difference between cetirizine and placebo was significant: &#8722;0.10 (95&#37; CI, &#8722;0.19, &#8722;0.01). However, when averaged over 6 weeks, neither active treatment was significantly different from placebo. The Rhinoconjunctivitis Quality-of-Life score was significantly improved by montelukast (p &#60; 0.05), but not by cetirizine, during 4 and 6 weeks. The treatment effect of montelukast, but not cetirizine, generally remained consistent through the 6 weeks of treatment. In pooled data, montelukast consistently improved DNSS versus placebo during all 6 weeks of treatment (&#8722;0.07 &#91;95&#37; CI, &#8722;0.10, &#8722;0.04&#93;). In conclusion, montelukast produced numerical improvement in daytime nasal symptoms and significant improvement in quality of life. In a pooled <I>post hoc</I> analysis, montelukast provided consistent improvement in daytime nasal symptoms over 6 weeks, supportive of an overall benefit in PAR.",
	pages = "296-304(9)",
	url = "http://www.ingentaconnect.com/content/ocean/aap/2007/00000028/00000003/art00008"
	doi = "doi:10.2500/aap.2007.28.3000"
}